{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Solid+Tumor+Malignancies&page=2", "query": { "condition": "Relapsed Solid Tumor Malignancies", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Solid+Tumor+Malignancies&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T12:45:11.691Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04111172", "title": "A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Colorectal Adenocarcinoma", "Gastric Adenocarcinoma", "Clinical Stage II Gastric Cancer AJCC v8", "Clinical Stage IIA Gastric Cancer AJCC v8", "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastric Cancer AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Malignant Solid Neoplasm", "Pathologic Stage II Gastric Cancer AJCC v8", "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIB Gastric Cancer AJCC v8", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Gastric Cancer AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastric Cancer AJCC v8", "Pathologic Stage IIIB Gastric Cancer AJCC v8", "Pathologic Stage IIIC Gastric Cancer AJCC v8", "Stage I Pancreatic Cancer AJCC v8", "Stage IA Pancreatic Cancer AJCC v8", "Stage IB Pancreatic Cancer AJCC v8", "Stage II Pancreatic Cancer AJCC v8", "Stage IIA Pancreatic Cancer AJCC v8", "Stage IIB Pancreatic Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Malignant Digestive System Neoplasm", "Small Intestinal Adenocarcinoma", "Stage III Small Intestinal Adenocarcinoma AJCC v8", "Stage IIIA Small Intestinal Adenocarcinoma AJCC v8" ], "interventions": [ { "name": "Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2020-11-10", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-07-24T12:45:11.691Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04111172" }, { "nct_id": "NCT01478685", "title": "A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Neoplasms", "Carcinoma, Transitional Cell", "Ovarian Neoplasms", "Fallopian Tube Neoplasms", "Peritoneal Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Pancreatic Ductal", "Tumor Virus Infections" ], "interventions": [ { "name": "CC-486", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "ABI-007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2011-11-29", "completion_date": "2015-11-17", "has_results": false, "last_update_posted_date": "2019-11-12", "last_synced_at": "2026-07-24T12:45:11.691Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • San Francisco, California • Indianapolis, Indiana + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01478685" }, { "nct_id": "NCT01495663", "title": "Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "I-131-CLR1404", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellectar Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2011-12", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2015-02-26", "last_synced_at": "2026-07-24T12:45:11.691Z", "location_count": 3, "location_summary": "Duarte, California • Washington D.C., District of Columbia • Madison, Wisconsin", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01495663" }, { "nct_id": "NCT04870944", "title": "CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Midline Glioma, H3 K27-Altered", "Metastatic Malignant Neoplasm in the Central Nervous System", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Diffuse Midline Glioma, H3 K27-Altered", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Primary Malignant Central Nervous System Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Primary Malignant Central Nervous System Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspirate", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "FACT Complex-targeting Curaxin CBL0137", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 63, "start_date": "2022-01-28", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-07-24T12:45:11.691Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04870944" }, { "nct_id": "NCT04332653", "title": "NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Any Advanced Solid Tumors", "Triple Negative Breast Cancer", "Non Small Cell Lung Cancer", "Small Cell Lung Cancer", "Microsatellite Stable Colorectal Cancer", "Pancreatic Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "NT-I7", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeoImmuneTech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 215, "start_date": "2020-06-10", "completion_date": "2025-01-13", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-07-24T12:45:11.691Z", "location_count": 8, "location_summary": "Tampa, Florida • Detroit, Michigan • St Louis, Missouri + 5 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04332653" }, { "nct_id": "NCT06620302", "title": "Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Childhood Fibrolamellar Carcinoma", "Recurrent Childhood Fibrolamellar Carcinoma", "Recurrent Childhood Malignant Solid Neoplasm", "Recurrent Fibrolamellar Carcinoma", "Recurrent Malignant Solid Neoplasm", "Refractory Childhood Fibrolamellar Carcinoma", "Refractory Childhood Malignant Solid Neoplasm", "Refractory Fibrolamellar Carcinoma", "Refractory Malignant Solid Neoplasm" ], "interventions": [ { "name": "Bcl-XL Proteolysis Targeting Chimera DT2216", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "39 Years", "sex": "ALL", "summary": "1 Year to 39 Years" }, "enrollment_count": 81, "start_date": "2025-06-12", "completion_date": "2031-12-30", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-07-24T12:45:11.691Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06620302" }, { "nct_id": "NCT04553692", "title": "Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Colorectal Cancer", "Non Hodgkin Lymphoma", "Sarcoma", "Chondrosarcoma", "Small Lymphocytic Lymphoma", "Chronic Lymphocytic Leukemia", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Aplitabart (IGM-8444)", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab (and approved biosimilars)", "type": "DRUG" }, { "name": "Birinapant", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IGM Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2020-09-23", "completion_date": "2025-01-20", "has_results": false, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-07-24T12:45:11.691Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04553692" }, { "nct_id": "NCT00075634", "title": "Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Neuroblastoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "decitabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 21, "start_date": "2003-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-07-24T12:45:11.691Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00075634" }, { "nct_id": "NCT01606878", "title": "Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Solid Neoplasm", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Neuroblastoma" ], "interventions": [ { "name": "Crizotinib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dexrazoxane Hydrochloride", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "13 Months to 21 Years" }, "enrollment_count": 46, "start_date": "2013-04-29", "completion_date": "2018-12-31", "has_results": true, "last_update_posted_date": "2024-01-05", "last_synced_at": "2026-07-24T12:45:11.691Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01606878" }, { "nct_id": "NCT06500819", "title": "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Sarcoma", "Osteosarcoma" ], "interventions": [ { "name": "B7-H3CART Dose (Intravenous)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 41, "start_date": "2024-07-11", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-07-24T12:45:11.691Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06500819" } ] }